CompletedNCT06291844Updated Mar 4, 2024

Ocular Trauma and COVID-19 in Indonesia

An observational study in Ophthalmological Disorder, Ocular Injury and COVID-19, sponsored by Prof. R. D. Kandou General Hospital. Completed at 1 site in Indonesia. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by Prof. R. D. Kandou General Hospital · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 13
Sex: All

Study summary

Ocular injuries, a significant contributor to avoidable blindness globally, impact approximately 55 million individuals each year. Prompt initial treatment is vital for improving vision, yet the scarcity of skilled eye specialists often results in overcrowding at advanced medical centers. Moreover, the COVID-19 outbreak has introduced distinct factors into the management of ocular trauma. This research investigated the epidemiology of ocular injuries during the pandemic and offered observations on the distinctive hurdles and trends encountered.

Conditions studied

Ophthalmological Disorder
Ocular Injury
COVID-19

Browse trials for

In context

Eye Diseases

388 studies on the registry are indexed under Eye Diseases; 62 are open to participants now.

This study's enrollment of 13 is below the median of 167 across 108 observational studies indexed under Eye Diseases.

Browse Eye Diseases studies →

Lead sponsor

Prof. R. D. Kandou General Hospital is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Ocular trauma patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Ocular Trauma Patients presenting between January 2021 to March 2022

Exclusion criteria

Exclusion Criteria:

Presenting on days outside the inclusion criteria

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 13 participants (actual)
Target follow-up: 2 Weeks
Patient registry: Yes

What researchers measure

Primary outcomes

Ocular Trauma
Time frame: 2 weeks

Study locations

1 site

Department of Ophthalmology, Prof. R. D. Kandou General Hospital - Faculty of Medicine, Sam Ratulangi University
Manado, North Sulawesi, Indonesia

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Mar 2022, 14 months.

Of 52 observational studies under Eye Diseases, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 86. This study's 14 months is below that.

Eye Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered: Mar 1, 2024
First posted: Mar 4, 2024
StartActual: Jan 1, 2021
Primary completionActual: Mar 31, 2022
CompletionActual: Jun 1, 2023
Last update: Mar 4, 2024

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT06291844
Lead sponsor: Prof. R. D. Kandou General Hospital
Responsible party: Vera Sumual (Vera Sumual, MD, PhD, Prof. R. D. Kandou General Hospital) — Principal investigator
First posted: Mar 4, 2024
Start date: Jan 1, 2021
Primary completion: Mar 31, 2022
Completion: Jun 1, 2023
Last update: Mar 4, 2024

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Eye Diseases →

Other studies from this sponsor

Prof. R. D. Kandou General Hospital

Start the discussion